` ALLR (Allarity Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ALLR
vs
S&P 500

Over the past 12 months, ALLR has underperformed S&P 500, delivering a return of -93% compared to the S&P 500's 9% growth.

Stocks Performance
ALLR vs S&P 500

Loading
ALLR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ALLR vs S&P 500

Performance Gap Between ALLR and GSPC
HIDDEN
Show

Performance By Year
ALLR vs S&P 500

Loading
ALLR
S&P 500
Add Stock

Competitors Performance
Allarity Therapeutics Inc vs Peers

S&P 500
ALLR
ABBV
AMGN
GILD
VRTX
Add Stock

Allarity Therapeutics Inc
Glance View

Market Cap
13.1m USD
Industry
Biotechnology

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-12-21. The firm is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The company uses its DRP companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by its DRP companion diagnostics platform. Its lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptor (VEGFR). Its second priority therapeutic candidate, stenoparib, is a selective inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). Its third priority therapeutic candidate is IXEMPRA (ixabepilone).

ALLR Intrinsic Value
Not Available
Back to Top